Secukinumab interactions

Conditions

Conditions in which Secukinumab needs care, as documented in this source.

• Infections

  Moderate

  There have been reports of serious infections, including infections with opportunistic pathogens, and reactivation of latent infections in patients receiving interleukin inhibitors. Treatment with these agents should not be initiated in patients with an active infection until the infection resolves or is adequately treated. Caution is recommended when considering the use of interleukin inhibitors in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.

  7 sources

  1. "Product Information. Stelara (ustekinumab)." Centocor Inc (2009):
  2. "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals (2009):
  3. "Product Information. Sylvant (siltuximab)." Janssen Biotech, Inc. (2014):
  4. "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals (2015):
  5. "Product Information. Nucala (mepolizumab)." GlaxoSmithKline (2015):
  6. "Product Information. Cinqair (reslizumab)." Teva Pharmaceuticals USA (2016):
  7. "Product Information. Tremfya (guselkumab)." Janssen Biotech, Inc. (2017):

• Inflammatory Bowel Diseases

  Moderate

  New onset and exacerbations of inflammatory bowel disease, in some cases serious, have been reported in patients treated with secukinumab. Caution should be used when prescribing secukinumab to patients with inflammatory bowel disease. Patients who are treated with secukinumab should be monitored for signs and symptoms of inflammatory bowel.

  1 source

  1. "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals (2015):

• Tuberculosis

  Moderate

  Before initiating certain interleukin inhibitors, patients should be screened for latent tuberculosis infection with a tuberculin skin test. Do not administer these agents to patients with an active tuberculosis infection. Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy. Anti-tuberculosis therapy should be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.

  4 sources

  1. "Product Information. Stelara (ustekinumab)." Centocor Inc (2009):
  2. "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals (2009):
  3. "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals (2015):
  4. "Product Information. Tremfya (guselkumab)." Janssen Biotech, Inc. (2017):